Table 2 Comparison of clinical features between patients with and without seroconversion

Age yr

Age ≤ 40

67 (34 %)

132 (66 %)

0.971

Age > 40

10 (33 %)

20 (67 %)

Gender

Female

19 (36 %)

33 (64 %)

0.613

Male

58 (33 %)

119 (67 %)

BMI (kg/m2)

<24

69(40 %)

102(60 %)

<0.001

≥24

8(14 %)

50(86 %)

HBV DNA level(log10copies/ml)

HBV DAN < 7

10(21 %)

38(79 %)

0.001

7 ≤ HBV DNA < 9

56(44 %)

71(56 %)

HBV DNA ≥ 9

11(20 %)

43(80 %)

Baseline ALT level (IU/L)

ALT ≥ 200

25(49 %)

26(51 %)

0.008

ALT < 200

52 (29 %)

126 (71 %)

Undetectable HBV DNA within 24 weeks

32 (54 %)

27 (46 %)

<0.001

Undetectable HBV DNA within 48 weeks

44 (40 %)

65 (60 %)

0.062

Normalization ALT within 12 weeks

12 (50 %)

12 (50 %)

0.232

Normalization ALT within 24 weeks

25 (56 %)

20 (44 %)

0.001

Reduction HBV DNA at 24 weeks from baseline

4.7 ± 1.2

4.0 ± 1.4

<0.001

Reduction HBV DNA at 48 weeks from baseline

5.0 ± 1.0

4.9 ± 1.3

0.609

Reduction ALT at 12 weeks from baseline

106.0 ± 109.0

61.1 ± 102.3

0.002

Reduction ALT at 24 weeks from baseline

123.6 ± 106.7

77.0 ± 91.1

0.001